Open-label glucocorticoids modulate dexamethasone trial results in preterm infants

Pediatrics

Volumn 126, Issue 4, 2010, Pages

  Onland, Wes ^a   Van Kaam, Anton H ^a   De Jaegere, Anne P ^a   Offringa, Martin ^a,b  

^a EMMA CHILDREN S HOSPITAL   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Cerebral palsy; Chronic lung disease; Glucocorticoids; Late rescue glucocorticoids; Mortality; Open label; Systematic review

Indexed keywords

DEXAMETHASONE; GLUCOCORTICOID; PLACEBO;

CEREBRAL PALSY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG POTENTIATION; HUMAN; INFANT; INFANT MORTALITY; LOW DRUG DOSE; LUNG DYSPLASIA; MAJOR CLINICAL STUDY; MORTALITY; NERVE CELL DIFFERENTIATION; OUTCOME ASSESSMENT; PERINATAL PERIOD; PREMATURITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT OUTCOME; ARTIFICIAL VENTILATION; BRONCHOPULMONARY DYSPLASIA; CHILD DEVELOPMENT; INFANT, PREMATURE, DISEASES; META ANALYSIS; NEWBORN; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURVIVAL RATE;

BRONCHOPULMONARY DYSPLASIA; CHILD DEVELOPMENT; DEXAMETHASONE; GLUCOCORTICOIDS; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; INFANT, PREMATURE, DISEASES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESPIRATION, ARTIFICIAL; SURVIVAL RATE;

EID: 77957699968     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2010-0597     Document Type: Review

References (48)

1. Halliday HL, Ehrenkranz RA, Doyle LW. Early (<8 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev. 2009;(1):CD001146
2. Halliday HL, Ehrenkranz RA, Doyle LW. Late (>7 days) postnatal corticosteroids for chronic lung disease in preterm infants. Cochrane Database Syst Rev. 2009;(1):CD001145
3. Walsh MC, Yao Q, Horbar JD, Carpenter JH, Lee SK, Ohlsson A. Changes in the use of postnatal steroids for bronchopulmonary dysplasia in 3 large neonatal networks. Pediatrics. 2006;118(5). Available at: www.pediatrics.org/cgi/ content/full/118/5/e1328
4. Shinwell ES, Lerner-Geva L, Lusky A, Reichman B. Less postnatal steroids, more bronchopulmonary dysplasia: a populationbased study in very low birth weight infants. Arch Dis Child Fetal Neonatal Ed. 2007;92(1):F30-F33
5. Yoder BA, Harrison M, Clark RH. Timerelated changes in steroid use and bronchopulmonary dysplasia in preterm infants. Pediatrics. 2009;124(2):673-679
6. Onland W, Offringa M, De Jaegere AP, van Kaam AH. Finding the optimal postnatal dexamethasone regimen for preterm infants at risk of bronchopulmonary dysplasia: a systematic review of placebo-controlled trials. Pediatrics. 2009;123(1):367-377
7. Onland W, De Jaegere APMC, Offringa M, van Kaam AHLC. Effects of a higher versus a lower dexamethasone dose on pulmonary and neurodevelopmental sequelae in preterm infants at risk for chronic lung disease: a meta-analysis. Pediatrics. 2008;122(1):92-101
8. Sheng D, Kim MY. The effects of non-compliance on intent-to-treat analysis of equivalence trials. Stat Med. 2006;25(7):1183-1199
9. Moher D, Schulz KF, Altman D. The CONSORT statement: revised recommendations for improving the quality of reports of parallelgroup randomized trials. JAMA. 2001;285(15):1987-1991 (Pubitemid 32366951)
10. Barrington KJ. The adverse neurodevelopmental effects of postnatal steroids in the preterm infant: a systematic review of RCTs. BMC Pediatr. 2001;1:1
11. Doyle LW, Halliday HL, Ehrenkranz RA, Davis PG, Sinclair JC. Impact of postnatal systemic corticosteroids on mortality and cerebral palsy in preterm infants: effect modification by risk for chronic lung disease. Pediatrics. 2005;115(3):655-661
12. Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Review of Interventions. Version 5.0.2. [updated September 2009]. Cochrane Collaboration; 2009. Available at: www.cochrane-handbook.org. Accessed July 28, 2010
13. Thompson SG, Higgins JPT. How should meta-regression analyses be undertaken and interpreted? Stat Med. 2002;21(11):1559-1573 (Pubitemid 34746063)
14. Cummings JJ, D'Eugenio DB, Gross SJ. A controlled trial of dexamethasone in preterm infants at high risk for bronchopulmonary dysplasia. N Engl J Med. 1989;320(23):1505-1510
15. Kothadia JM, O'Shea TM, Roberts D, Auringer ST, Weaver RG III, Dillard RG. Randomized placebo-controlled trial of a 42-day tapering course of dexamethasone to reduce the duration of ventilator dependency in very low birth weight infants [published correction appears in Pediatrics. 2004; 114(6):1746]. Pediatrics. 1999;104(1 pt 1):22-27
16. Scott SM, Backstrom C, Bessman S. Effect of five days of dexamethasone therapy on ventilator dependence and adrenocorticotropic hormone-stimulated cortisol concentrations. J Perinatol. 1997;17(1):24-28
17. Ariagno RL, Sweeney TE, Baldwin RB, Inguillo D, Martin D. Dexamethasone effects on lung function and risks in three week old ventilator dependent preterm infants [abstract]. Am Rev Respir Dis. 1987;135:A125
18. Kari MA, Heinonen K, Ikonen RS, Koivisto M, Raivio KO. Dexamethasone treatment in preterm infants at risk for bronchopulmonary dysplasia. Arch Dis Child. 1993;68(5 spec No.):566-569
19. Romagnoli C, Vento G, Zecca E, et al. A controlled trial of dexamethasone in preterm infants at risk of chronic lung disease. [in Italian]. Riv Ital Pediatr. 1998;24:283-288 (Pubitemid 28308586)
20. Vento G, Matassa PG, Zecca E, et al. Effect of dexamethasone on tracheobronchial aspirate fluid cytology and pulmonary mechanics in preterm infants. Pharmacology. 2004;71(3):113-119 (Pubitemid 38716225)
21. Doyle LW, Davis PG, Morley CJ, McPhee A, Carlin JB; DART Study Investigators. Low-dose dexamethasone facilitates extubation among chronically ventilator-dependent infants: a multicenter, international, randomized, controlled trial. Pediatrics. 2006;117(1):75-83
22. Vincer MJ, Allen AC. Double blind randomized controlled trial of 6-day pulse of dexamethasone for very low birth weight infants (VLBW < 1500 grams) who ventilator dependent at 4 weeks of age [abstract]. Pediatr Res. 1998;43(4):201A
23. Collaborative Dexamethasone Trial Group. Dexamethasone therapy in neonatal chronic lung disease: an international placebo-controlled trial. Pediatrics. 1991;88(3):421-427
24. Ohlsson A, Calvert SA, Hosking M, Shennan AT. Randomized controlled trial of dexamethasone treatment in very-low-birthweight infants with ventilator-dependent chronic lung disease. Acta Paediatr. 1992;81(10):751-756
25. Kovács L, Davis GM, Faucher D, Papageorgiou A. Efficacy of sequential early systemic and inhaled corticosteroid therapy in the prevention of chronic lung disease of prematurity. Acta Paediatr. 1998;87(7):792-798
26. Walther FJ, Findlay RD, Durand M. Adrenal suppression and extubation rate after moderately early low-dose dexamethasone therapy in very preterm infants. Early Hum Dev. 2003;74(1):37-45 (Pubitemid 37152488)
27. Durand M, Sardesai S, McEvoy C. Effects of early dexamethasone therapy on pulmonary mechanics and chronic lung disease in very low birth weight infants: a randomized, controlled trial. Pediatrics. 1995;95(4):584-590
28. Avery GB, Fletcher AB, Kaplan M, Brudno DS. Controlled trial of dexamethasone in respirator-dependent infants with bronchopulmonary dysplasia. Pediatrics. 1985;75(1):106-111
29. American Academy of Pediatrics, Committee on Fetus and Newborn; Canadian Paediatric Society, Fetus and Newborn Committee. Postnatal corticosteroids to treat or prevent chronic lung disease in preterm infants. Pediatrics. 2002;109(2):330-338
30. Wright CC, Sim J. Intention-to-treat approach to data from randomized controlled trials: a sensitivity analysis. J Clin Epidemiol. 2003;56(9):833-842
31. Halliday HL. Guidelines on neonatal steroids. Prenat Neonatal Med. 2001;6(6):371-373
32. Rademaker KJ, Groenendaal F, van BF, de Vries LS, Uiterwaal CS. The DART study of low-dose dexamethasone therapy. Pediatrics. 2007;120(3):689-690 (Pubitemid 47358321)
33. Eichenwald EC, Stark AR. Are postnatal steroids ever justified to treat severe bronchopulmonary dysplasia? Arch Dis Child Fetal Neonatal Ed. 2007;92(5):F334-F337
34. Bose CL, Laughon MM. Corticosteroids and chronic lung disease: time for another randomized, controlled trial? Pediatrics. 2005;115(3):794
35. Halliday HL, Ehrenkranz RA, Doyle LW. Delayed (>3 weeks) postnatal corticosteroids for chronic lung disease in preterm infants. Cochrane Database Syst Rev. 2003;(1):CD001145
36. Porta N, Bonet C, Cobo E. Discordance between reported intention-to-treat and per protocol analyses. J Clin Epidemiol. 2007;60(7):663-669
37. O'Shea TM, Kothadia JM, Klinepeter KL, et al. Randomized placebo-controlled trial of a 42-day tapering course of dexamethasone to reduce the duration of ventilator dependency in very low birth weight infants: outcome of study participants at 1-year adjusted age. Pediatrics. 1999;104(1 pt 1):15-21
38. Doyle LW, Davis PG, Morley CJ, McPhee A, Carlin JB; DART Study Investigators. Outcome at 2 years of age of infants from the DART study: a multicenter, international, randomized, controlled trial of low-dose dexamethasone. Pediatrics. 2007;119(4):716-721
39. Jones R, Wincott E, Elbourne D, Grant A. Controlled trial of dexamethasone in neonatal chronic lung disease: a 3-year follow-up. Pediatrics. 1995;96(5 pt 1):897-906
40. Harkavy KL, Scanlon JW, Chowdhry PK, Grylack LJ. Dexamethasone therapy for chronic lung disease in ventilator-and oxygen-dependent infants: a controlled trial. J Pediatr. 1989;115(6):979-983
41. Brozanski BS, Jones JG, Gilmour CH, et al. Effect of pulse dexamethasone therapy on the incidence and severity of chronic lung disease in the very low birth weight infant. J Pediatr. 1995;126(5 pt 1):769-776
42. Hofkosh D, Brozanski BS, Edwards DE, Williams LA, Jones JG, Cheng KP. One year outcome of infants treated with pulse dexamethasone for prevention of BPD [abstract]. Pediatr Res. 1995;37:259A
43. Lauterbach R, Szymura-Oleksiak J, Pawlik D, Warchol J, Lisowska-Miszczyk I, Rytlewski K. Nebulized pentoxifylline for prevention of bronchopulmonary dysplasia in very low birth weight infants: a pilot clinical study. J Matern Fetal Neonatal Med. 2006;19(7):433-438 (Pubitemid 44272918)
44. Yoder MC Jr, Chua R, Tepper R. Effect of dexamethasone on pulmonary inflammation and pulmonary function of ventilator-dependent infants with bronchopulmonary dysplasia. Am Rev Respir Dis. 1991;143(5 pt 1):1044-1048
45. Papile LA, Tyson JE, Stoll BJ, et al. A multicenter trial of two dexamethasone regimens in ventilator-dependent premature infants. N Engl J Med. 1998;338(16):1112-1118
46. Stoll BJ, Temprosa M, Tyson JE, et al. Dexamethasone therapy increases infection in very low birth weight infants. Pediatrics. 1999;104(5). Available at: www.pediatrics.org/cgi/content/full/104/5/e63
47. Kazzi NJ, Brans YW, Poland RL. Dexamethasone effects on the hospital course of infants with bronchopulmonary dysplasia who are dependent on artificial ventilation. Pediatrics. 1990;86(5):722-727
48. Noble-Jamieson CM, Regev R, Silverman M. Dexamethasone in neonatal chronic lung disease: pulmonary effects and intracranial complications. Eur J Pediatr. 1989;148(4):365-367